EF001 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 聯合醫務集團有限公司 | | 股份代號 | 00722 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年6月30日止年度之末期股息 | | 公告日期 | 2025年9月17日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年6月30日 | | 宣派股息的報告期末 | 2025年6月30日 | | 宣派股息 | 每 股 0.019 HKD | | 股東批准日期 | 2025年11月21日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.019 HKD | | 匯率 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 UMP HEALTHCARE HOLDINGS LIMITED 噛⠡桂⛪涐⭒㯡洒軴⠑ 荵㪇 汇㯒啯ㅤ躳▌踁偽逓㯡洒軴 ⠑荶 荵嚎⋚⊿屽莇722荶 截至2025年6月30日止年度之 附註b： 經非經常性一次性商譽及投資項目減值及來自溢利保證的收益調整後的未計利息、稅項、 折舊及攤銷前的利潤。 2 聯合醫務集團有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈本公司 及其附屬公司（統稱「本集團」）截至2025年6月30日止年度的綜合業績，連同截至 2024年6月30日止年度的比較數字如下： 綜合損益表 截至2025年6月30日止年度 | | | 2025年 | 2024年 | | --- | --- | --- | --- | | | 附註 | 千港元 | 千港元 | | 收入 | 5 | 726,949 | 748,489 | | 其他收入及收益 | 6 | 14,181 | 35,895 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 噛⠡桂⛪涐⭒㯡洒軴⠑ 荵㪇 汇㯒啯ㅤ躳▌踁偽逓㯡洒軴 ⠑荶 荵嚎⋚⊿屽莇722荶 UMP HEALTHCARE HOLDINGS LIMITED 更改公司標誌 聯合醫務集團有限公司（「本公司」）董事會（「董事會」）欣然宣佈，本公司已採用新 的公司標誌，即時生效。新舊標誌如下，以資識別： 舊標誌 新標誌 UMP HEAL 新標誌獲採納後，將用於本公司的相關公司文件（包括但不限於中期報告及年報、 THCARE HOLDINGS LIMITED 公告、通函、通告、股票及新聞稿），並會在本公司網站上展示。 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 722) 更改本公司標誌將不會影響本公司現有股東的任何權利。所有印有舊標誌的本公 司現有已發行股票將繼續有效作為本公司該等股份的所有權文件，並繼續有效作 1 買賣、 ...

格隆汇9月3日丨联合医务(00722.HK)宣布，公司将于2025年9月17日(星期三)举行董事会会议，以(其中 包括)审批集团截至2025年6月30日止财政年度之综合年度业绩及其刊发，考虑建议派付末期股息(如 有)，以及处理其他事项。 ...

UMP HEALTHCARE HOLDINGS LIMITED 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於 開曼群島註冊成立的有限公 司） （股份代號：722） 董事會召開日期 聯合醫務集團有限公司（「本公司」及連同其附屬公司「本集團」）之董事會（「董事會」） 謹此宣佈，本公司將於2025年9月17日（星期三）舉行董事會會議，以（其中包括） 審批本集團截至2025年6月30日止財政年度之綜合年度業績及其刊發，考慮建議派 付末期股息（如有），以及處理其他事項。 於本公告日期，本公司執行董事為孫耀江醫生（主席）、孫文堅醫生（副主席兼聯 席行政總裁）、郭卓君女士（聯席行政總裁）、曾安業先生、李柏祥醫生；非執行 董事為李家聰博士；以及獨立非執行董事為李聯偉先生、李國棟醫生及楊德斌先生。 承董事會命 聯合醫務集團有限公司 公司秘書 張志華 香港，2025年9月3日 ...

本月底法定/註冊股本總額： HKD 5,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 聯合醫務集團有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00722 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 5,000,000,000 | | HKD | | 0.001 HKD | | 5,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 5,000,000,000 | HKD ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00722 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 810,955,244 | | 0 | | 810,955,244 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 810,955,244 | | 0 | | 810,955,244 | 第 2 頁 共 10 頁 v 1.1.1 公司名稱: 聯合醫務集團有限公司 呈交日期: 2025年8月1日 ...

持續關連交易 醫療服務框架協議 董事會欣然宣佈，於2025年7月31日，本公司與仁德醫健訂立協議，由2025年8月 1日起至2028年6月30日止。根據協議，(1)仁德醫健須或促使仁德醫健集團的成 員公司以非獨家方式向本集團提供仁德醫療相關服務，及(2)本公司須或促使本 集團的成員公司以非獨家方式向仁德醫健集團提供聯合醫務醫療相關服務。協 議項下之仁德醫療相關服務於第1年、第2年及第3年的建議年度上限分別為 50,000,000港元、55,000,000港元及60,000,000港元。協議項下之聯合醫務醫療相 關服務於第1年、第2年及第3年的建議年度上限分別為30,000,000港元、 35,000,000港元及43,000,000港元。 於本公告日期，仁德醫健為本公司多間附屬公司的主要股東的附屬公司，故於 附屬公司層面為本公司之關連人士。因此，就上市規則第14A章而言，協議項下 擬進行之交易構成本公司與附屬公司層面之關連人士的持續關連交易，且由於 協議項下擬進行之交易按年計算之一個或多個適用百分比率超過5%但低於 25%，故須遵守上市規則第14A章項下之申報、公告、通函、獨立財務意見及股 東批准之規定。根據 ...

Group 1 - The core viewpoint of the news highlights the recent performance of United Medical (00722.HK) in the Hong Kong stock market, noting a 6.74% increase in share price despite a broader market decline [1] - Over the past month, United Medical has seen a cumulative increase of 5.95%, and a year-to-date increase of 12.1%, which is lower than the Hang Seng Index's increase of 18.2% [2] - Financial data shows that as of December 31, 2024, United Medical achieved total revenue of 344 million yuan, a year-on-year decrease of 1.22%, while net profit attributable to shareholders was 16.62 million yuan, a year-on-year increase of 14.55% [2] Group 2 - Currently, there are no institutional investment ratings for United Medical [3] - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -21.64 times, with a median of 0.36 times; United Medical's P/E ratio stands at 8.41 times, ranking 10th in the industry [3] - United Medical Group Limited, established in 1990, is a leading healthcare platform in Hong Kong and Macau, providing diverse medical services and collaborating with enterprises and insurance companies to manage healthcare benefit plans [4]

Financial Performance - Revenue for the six months ended December 31, 2024, was HK$371,271,000, a decrease of 1.2% from HK$375,845,000 in the same period of 2023[11] - EBITDA increased by 17.0% to approximately HK$46,552,000 from HK$39,772,000 year-on-year[11] - Profit for the period rose by 45.7% to HK$19,246,000 compared to HK$13,209,000 in the previous year[11] - Profit attributable to owners of the Company increased by 14.6% to HK$17,948,000 from HK$15,668,000[11] - Basic and diluted earnings per share improved by 14.8% to 2.25 HK cents from 1.96 HK cents[11] - Total consolidated revenue decreased by 1.2% from HK$375.8 million in 1H FY23/24 to HK$371.3 million in 1H FY24/25[74] Cash and Assets - Cash, bank balances, and deposits increased by 18.4% to HK$303,259,000 from HK$256,139,000[11] - Net current assets rose by 6.0% to HK$231,769,000 compared to HK$218,719,000[11] - The Group's current assets increased to HK$532.97 million as of December 31, 2024, compared to HK$489.08 million as of June 30, 2024, while current liabilities rose to HK$301.20 million from HK$270.36 million[113] - The net current assets as of December 31, 2024, were HK$231.77 million, reflecting an increase from HK$218.72 million as of June 30, 2024[113] - Free cash and bank deposits amounted to approximately HK$301.2 million as of December 31, 2024, up from HK$253.3 million as of June 30, 2024[114] Operational Efficiency - Gross profit margin was maintained, reflecting improved operational efficiency[18] - Manpower costs improved by 4.4% year-on-year due to workforce optimization[18] - Rental expenses and depreciation of right-of-use assets decreased by approximately 15.0% year-on-year due to effective facility consolidations[18] - The company has implemented operational efficiency measures that resulted in a 4.4% reduction in human resources expenses year-on-year[21] - Professional services expenses decreased by 2.6% from HK$137.1 million to HK$133.5 million, attributed to increased operational efficiency[78] Revenue Segments - In the first half of FY24/25, total revenue for the Hong Kong & Macau Corporate Healthcare Solution Services segment increased by 4.1%, from HK$128.8 million in 1H FY23/24 to HK$134.1 million in 1H FY24/25[23] - Revenue from the Hong Kong & Macau Clinical Healthcare Services segment declined from HK$299.4 million in 1H FY23/24 to HK$289.2 million in 1H FY24/25, reflecting a decrease in patient visits and body check consumers[31] - Revenue from Mainland China segment increased from HK$19.3 million in 1H FY23/24 to HK$20.0 million in 1H FY24/25, reflecting a year-on-year growth of approximately 3.6%[37] - Revenue from corporate healthcare solution services increased by 4.1% to HK$134.1 million, while clinical healthcare services in Hong Kong decreased by 3.4% to HK$289.2 million[67] Strategic Initiatives - The company has established strategic partnerships and new service points in Mainland China, enhancing its network and service accessibility[24] - The company has diversified income sources by introducing new services such as Traditional Chinese Medicine (TCM) and physiotherapy to mitigate risks from declining immigration medical examination volumes[33] - The company won a government tender for nurse clinic services and allied health services, enhancing its service offerings in primary care[34] - The integration of artificial intelligence (AI) technology into medical imaging services is expected to improve diagnostic capabilities and patient care efficiency[34] - The company aims to expand its presence in the Greater Bay Area by partnering with local organizations to enhance outpatient care services[39] Future Outlook - The outlook for the second half of FY24/25 remains cautiously optimistic, with a focus on operational excellence and digital transformation to navigate global uncertainties[40] - Key priorities include improving cash flow generation and managing working capital effectively, with plans to streamline invoicing and payment collection processes[41] - Investment in a new patient management system is set to launch in the second half of FY24/25, aimed at enhancing patient data management and overall experience[49] - The company is focusing on preventive medicine and integrated care models to address rising healthcare costs and improve service delivery[54] Corporate Governance - The Audit Committee reviewed the unaudited interim results for the six months ended December 31, 2024, confirming compliance with relevant accounting standards and legal requirements[168] - The Company is committed to high standards of corporate governance and has confirmed compliance with the Corporate Governance Code during the reporting period[158] Shareholder Information - As of December 31, 2024, the total number of shares held by directors and the chief executive amounts to 389,346,659, representing approximately 48.01% of the issued shares[175] - The total number of issued shares as of December 31, 2024, is 810,955,244[177] - The Board declared an interim dividend of HKD 1.40 cents per ordinary share for the six months ended December 31, 2024, an increase from HKD 1.30 cents in the previous fiscal year[154]